MediCapture Launches The TRS Pro Wireless Medical Tablet Recorder System

MediCapture, a global leader in medical imaging systems, announced today that it is launching the TRS Pro™, a new and convenient approach to how surgeries are recorded and managed.

The first of its kind, TRS Pro comes with MediCapture’s advanced MVR™ medical video recorder and a wireless tablet that can be connected to the recorder or used wirelessly throughout the operating room as a remote control or to stream video in real time — giving surgical teams more freedom of movement during surgeries.

The tablet also can be used after surgery away from the operating room to review and manage patient sessions.

At the heart of the TRS Pro is the non-computer based Smart Workflow interface, which powers the unique functionality of the MVR Manager and MVR Secure.

With MVR Manager, surgeons can:

  • Securely manage patient folders
  • Edit videos and images, annotate and more
  • Easily archive and store recordings
  • Develop reports and send to printer of choice via WiFi

MVR Secure ensures recordings are safe by:

  • Preventing files from becoming lost with Automatic Video Repair
  • Fully protecting against external viruses with Read Only OS
  • Password-protected remote access for IT Administrators

The TRS Pro is also customizable.  It comes with full HD resolution, but can be easily upgraded to 4K Ultra HD resolution with a simple activation key code provided by MediCapture.  The recording system also can be upgraded with DICOM functionality with an activation key.

“We developed TRS Pro to be versatile for surgical teams, giving them the option to control it by preference,” says Mike Bishop, CEO of MediCapture.  “Some may want to connect the tablet directly to the recorder, but others may prefer to use it from anywhere in the operating room via WiFi.  Surgeons can also take the tablet with them after surgery to annotate files, print reports, archive and more.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”